Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of microorganism in treatment and/or prevention of immune-mediated intestinal diseases

An intestinal disease, immune-mediated technology, applied to products containing Bifidobacterium breve, which can address the therapeutic role in the treatment and/or prevention of intestinal diseases induced by immune checkpoint blockade no clear questions

Active Publication Date: 2019-05-17
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is still unclear which bifidobacteria in the genus Bifidobacterium have therapeutic effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of microorganism in treatment and/or prevention of immune-mediated intestinal diseases
  • Application of microorganism in treatment and/or prevention of immune-mediated intestinal diseases
  • Application of microorganism in treatment and/or prevention of immune-mediated intestinal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1 confirms functional bacterial strain

[0072] 1. Preparation of colitis model mice induced by CTLA-4 blockade

[0073] Give mice vancomycin (0.5g / L, Sigma) to change intestinal commensal bacteria, and after at least 14 days, add 2-4% heparin-like sulfated polysaccharide (DSS, MP Biomedicine) into the drinking water of mice and take 7 -12 days. At the beginning of DSS treatment, mice were injected with 200ug anti-CTLA-4 mAb.

[0074] 2. Test plan

[0075] 1) Body weight change test

[0076] The colitis model mice were inoculated with four types of bifidobacteria: Bifidobacterium breve (B.Breve), Bifidobacterium longum (B.Longum), Bifidobacterium bifidum (Bifidum), Bifidobacterium lactis ( B.Angulatum), each mouse was orally fed with 1x10 9 CFU, the control group was given the same amount of PBS, and then the body weight was monitored every day.

[0077] Inoculate colitis model mice with three kinds of lactic acid bacteria: Lactobacillus plantarum (L.Pl...

Embodiment 2

[0086] Example 2 Effects of Bifidobacteria on the composition of intestinal flora and the abundance of intestinal bacteria

[0087] Bifidobacterium breve modulates CTLA-4 blockade-induced intestinal disease in relation to Treg cells. This assay is expected to verify whether Treg cells directly regulate the microbial composition and gut microbiota composition produced by Bifidobacterium breve in individuals with Treg cells and Influence of intestinal bacterial abundance.

[0088] 1. Mice and groups:

[0089] The mice used in the experiment were 6-14-week-old female mice, which were raised in a specific pathogen-free facility of Shanghai Jiaotong University. Mouse experiments were approved by the Animal Care and Use Committee of Shanghai Jiao Tong University School of Medicine.

[0090] Take 50 C57BL / 6N mice and randomly divide them into five groups, 10 mice in each group. One DTR is carried on the Treg cells of two groups of mice to instantly deplete Treg cells (De-Treg), and...

Embodiment 3

[0100] Example 3 Effect of Bifidobacterium breve on the expression level of inflammation-related genes

[0101] 1. Bifidobacterium breve inhibits the proliferation of Treg cells

[0102] The effector T cells (Teff) were co-cultured with the Treg cells treated with Bifidobacterium breve, and the effector T cells were co-cultured with the Treg cells treated with PBS, and the proliferation ratio was compared. The results were as follows: Image 6 As shown, the proliferative ability of Treg cells decreased significantly after being treated with Bifidobacterium breve.

[0103] 2. Deletion of the IL10 gene and / or blocking the expression of IL-22 can cause intestinal diseases

[0104] IL10 knockout mice, IL-22 antibody-injected and IgG-treated mice (control group) were prepared according to the steps in Example 1 to prepare CTLA-4 blocking-induced colitis model mice, and then the three kinds of mice were treated with Administration of Bifidobacterium breve. The body weight change,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of microorganism in treatment and / or prevention of immune-mediated intestinal diseases. The microorganism is bifidobacterium and / or lactobacillus. Preferably, the intestinal diseases are induced by CTLA-4 and / or PD-1 detection point blockage.

Description

technical field [0001] The present invention relates to the technical field of intestinal flora, in particular to a product containing Bifidobacterium Breve for the treatment and / or prevention of intestinal diseases and its application, especially in the treatment of Bifidobacterium Breve And / or prevent intestinal diseases induced by immune checkpoint blockade. Background technique [0002] Bifidobacteria are the quintessential gut flora associated with body weight, digestion, resistance to infection, risk of autoimmune disease, and the body's response to cancer treatment drugs. [0003] Immune checkpoint therapy has achieved great success in clinical treatment. Immune checkpoint blockade drugs promote T cell anti-tumor immunity by reducing inhibitory signals that block T cell signaling and function. Monoclonal antibodies (mAbs) against CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) have had success in the treatment of melanoma and were the first to be approved by th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A61K35/744A61K39/395A61P1/00A61P35/00A23L33/135
Inventor 王锋
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com